GeoSolar Technologies Inc. Poised to benefit as Solar Energy Costs Sink Below Conventional Energy Prices

 

• Renewable energy demand has seen a further increase on the back of rising utility costs
• Orlando’s Utility Commission recently introduced its third utility price hike of the year and have warned of another potential increase come January 2023
• Meanwhile, solar energy prices have now fallen below those of conventional, fossil-fuel generated energy 
• GeoSolar Technologies proprietary home solution provides homeowners with a mix of lower utility costs and energy independence

Speaking at the United Nation’s Climate Change Conference (COP26) last year, Richa Sharma, leader of the Indian delegation stated “The meagre carbon budget is first and foremost the right and entitlement of developing countries” (https://ibn.fm/UMDqX). At the time, Sharma was arguing that developing nations should be given first right towards using carbon-intensive fossil fuels to drive their respective economies in the face of global carbon emission quotas; in fact and only months prior to the meeting, the International Energy Agency had forecast that India’s installed capacity of coal would grow by 80 percent between 2018 and 2040 (https://ibn.fm/GRRx7). A year later, the agency saw fit to revise down that figure to just 10 percent. Renewable energy sources like wind and solar have seen their cost structures decline dramatically in recent years, arriving at cost parity with fossil-fuel powered energy sources in several global markets. The decline in renewable energy costs coupled with the exponential rise in fossil fuel prices have led to a dramatic increase in renewable energy demand, a phenomenon which the likes of climate technology company GeoSolar Technologies (“GST”), are seeking to capitalize on.

Despite their higher upfront costs – it costs an average of $18,000 to install a 6kW grid-tied solar system, solar energy home systems have long posed an attractive investment proposition for homeowners. Solar panels have a usable lifespan of 25 years on longer; homeowners who install solar panels tend to break even within six to ten years due to utility bill savings (https://ibn.fm/dJ6Pc) providing for an attractive return on investment. Whilst the investment case for solar panels has been generally well-understood, recent, volatile moves in hydrocarbon prices – US natural gas prices spiked to a 14 year high in August – have served as a further incentive for homeowners seeking to shift towards renewable energy sources.

Florida’s Orlando Utilities Commission (“OUC”) lately provided a stark illustration of the ongoing paradigm shift within energy prices. The municipal utility recently approved a rate increase for most of its residential customers, leading utility bills to rise by anywhere between $5 to $15 a month. Having already been obliged to raise rates thrice this year, the OUC did not rule out a further hike come January. However, and unlike electricity generated from fossil fuels, solar energy prices have remained unchanged.

OUC’s Chief Financial Officer, Mindy Brenay elaborated on the change in electricity pricing as well as the relative attraction of solar power in the current environment.

“Community solar has [historically been priced at a premium over traditional fuel pricing, and that has been the case since we have implemented solar. The price of solar has continued to come down, but it has traditionally been higher than our standard fuel price Now with this unusual spike we’re seeing in fuel, we want to do everything we can to lower the fuel costs. So, these solar costs, which are now actually lower than our traditional, are being blended in to give all customers the opportunity to share in those lower costs from solar,” (https://ibn.fm/eD9Nk).

GeoSolar Technologies have sought to build upon the growing move towards solar energy adoption thorough a multi-pronged approach which looks to electrify homes using green energy sources. From solar panels on roofs through to geothermal heat pumps which take advantage of the warmth of the earth’s core and advanced CERV 2 air purification systems designed to manage indoor air quality in an efficient and intelligent manner, GeoSolar’s proprietary SmartGreen™ Home solution has been designed to dramatically increase the energy efficiency of a conventional household. Moreover, the technology voids the need for households to depend on conventional utilities or pay utility bills. In fact, a study carried out by the company found that a traditional utility-powered home would possess a carbon footprint of upwards of 8 tons of CO2/year whilst paying annual utility bills of $2,700; in contrast, a GeoSolar-powered home would result in a negligible carbon footprint whilst disbursing less than $100 per annum in utility bills (https://ibn.fm/AGcTL).

Providing homeowners with a heady combination of lower utility costs and ultimate energy independence, GeoSolar Technologies and its proprietary energy solution find themselves ideally situated to satisfy one of the fastest growing sources of consumer demand in the United States, today.

For more information, visit the company’s website at www.GeoSolarPlus.com.

NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Lexaria Bioscience Corp. (NASDAQ: LEXX) Addressing Hypertensive Patients’ Concerns with DehydraTECH-CBD

 

• Lexaria is a global innovator in drug delivery platforms whose lead technology is DehydraTECH(TM)
• Studies have shown that DehydraTECH increases the intestinal bioabsorption of bioactive compounds by as much as 27 times, hence resulting in greater bioavailability; pre-clinical and human studies have demonstrated that DehydraTECH-CBD enables absorption increases of between 100% and 500% The studies have also shown that DehydraTECH-CBD results in a rapid and sustained drop in blood pressure among hypertension patients
• Lexaria, which believes there is a significant unmet demand for cost-effective hypertensive treatments with few or no side effects, is working toward commercializing DehydraTECH-CBD to satisfy this demand

Currently, roughly 20% of people diagnosed with hypertension take medication, with the remaining majority noting that the medications’ side effects substantially outweigh the benefits. This has often constrained the fight against hypertension, the most common cardiovascular disease worldwide, which affects more than one billion people and is associated with long-term morbidities such as heart disease, stroke, and even death.

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, believes the hesitance or refusal to take medication presents a significant unmet demand for more tolerable, cost-effective anti-hypertensive treatments and has been working to bring such treatments to the masses. Specifically, the company is developing a new potential treatment with few or no side effects to address a majority of hypertensive patients’ concerns about taking hypertension medication.

The company’s drug candidate, DehydraTECH(TM)-processed CBD, has been the subject of animal and human studies, which have yielded “extremely promising early results,” according to Prof. Philip Ainslie, PhD., Lead Investigator in Lexaria’s human hypertension studies, who was recently interviewed by PCG Digital (https://ibn.fm/gKxMY). These results are thanks, in part, to the improved performance offered by the company’s patented DehydraTECH drug delivery technology.

The technology, Lexaria’s studies have shown, increases the intestinal bioabsorption of bioactive compounds by as much as 27 times. This results in greater bioavailability of these therapeutics at lower doses. Nowhere else is this as apparent as in the case of CBD. CBD or cannabidiol, Prof. Ainslie explained, “is a complex fat-soluble molecule and is known to have poor absorption characteristics. Typically, only about 6% of what is orally ingested enters the bloodstream. Through our pre-clinical and human studies, we have shown that DehydraTECH technology enables absorption increases of between 100% and 500%.”

Additional results from the company’s 2021 studies – HYPER-H21-1, HYPER-H21-2, and HYPER-H21-3 – have demonstrated that DehydraTECH-CBD caused a rapid and sustained reduction in blood pressure among hypertensive volunteers. “The improvements in blood pressure results were particularly remarkable given the fact that many existing drugs used to treat hypertension require several weeks of treatments and/or combination dosing before they produce comparable reductions in blood pressure,” underlined Prof. Ainslie.

Just recently, Lexaria completed its most comprehensive human hypertension study, HYPER-21-4, which enabled them to gather critical data monitoring the safety and efficacy of the DehydraTECH-CBD formulation over a prolonged period. The study, Prof. Ainslie noted, will allow the company to evaluate the formulation’s potential for longer-term health benefits.

The completed studies are, however, just the beginning – Lexaria plans to undertake clinical trials with the FDA that seek to demonstrate the safety and tolerability profile relative to conventional anti-hypertensive medications. These trials will also aim to avoid serious adverse events at clinically efficacious doses.

According to the Lead Investigator, establishing safety is extremely important because, though often well-tolerated, CBD can potentially cause liver toxicity, particularly when given in the high therapeutic doses required for conditions such as epilepsy or hypertension. As a baseline, Epidiolex, the only FDA-approved CBD drug, has an approved dose of 10mg per kilogram of body weight, given twice daily. Lexaria, however, believes its DehydraTECH technology has the potential to reduce the prescribed doses because of its ability to enhance CBD’s bioavailability.

“There could be significant benefits in allowing its dosing to be reduced while maintaining therapeutic delivery levels, and we have already been investigating a range of doses lower than those already approved by FDA for Epidiolex, for example,” Prof. Ainslie emphasized.

The completed and planned research is part of a greater goal: commercialization. To that end, Lexaria has engaged the FDA resulting in confirmation that the agency supported the company’s proposal to pursue the abbreviated 505(b)(2) New Drug Application (“NDA”) (https://ibn.fm/tZz5Y). The abbreviated pathway enables a faster route to commercial approval than the traditional pathway.

Presently, and following the confirmation, the company is working on preparatory work that will facilitate the filing of an Investigational New Drug (“IND”) application and is on track to file by year’s end or early 2023. Thereafter, and upon approval of the application, Lexaria expects to commence its proposed US-based Phase 1b clinical trial involving about 100 hypertension patients. As part of the study, the participants will receive a dose of DehydraTECH-CBD to evaluate the safety and efficacy of the formulation as well as 24-hour ambulatory blood pressure.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Golden Matrix Group Inc. (NASDAQ: GMGI) Rides Growing iGaming Wave with Record-Breaking Revenues, Market Expected to Double by 2027

 

• iGaming market expected to double from $173 billion to over $340 billion by 2027
• GMGI recently posted record-breaking Q3 revenue results, 16 non-stop profitable quarters
• GMGI’s industry-standard GM-Ag System provides access to 10,000+ games, simplifies payment options, leverages data analytics to provide total 360-degree performance visibility

The iGaming market continues its rapid pace of growth with expectations it will double from $173 billion to over $340 billion by 2027 (https://ibn.fm/8JO3m).  Golden Matrix Group (NASDAQ: GMGI), a developer and licensor of online gaming platforms and systems, continues to ride the rising wave of industry growth with non-stop consecutive profitable quarters and record-breaking quarterly revenues (https://ibn.fm/AATls).

“Our ability to generate increasing revenues with quarter-after-quarter of profitability attests to the strengths of our B2B and B2C platforms,” said GMGI CEO Anthony Brian Goodman. “Because of the highly competitive nature of our industry, we are continually upgrading our systems and gaming content offerings to support the needs of our millions of participants.”

iGaming is a diverse industry comprising numerous forms of online gambling, including regular online casinos, poker rooms, e-sports betting, crypto casinos, and binary trading. Factors contributing to industry growth are linked to the increased availability of smartphones, laptops, and virtual reality headsets. In addition, Covid-19 pandemic restrictions catalyzed industry expansion by driving people to online activities when government mandates forced casinos and other entertainment venues to close.

Casino aggregator platforms additionally fuelled industry growth by reducing barriers to entry and easily connecting operators to suppliers, payment systems, and gaming content. GMGI’s next generation GM-Ag System – the industry standard – provides access to 10,000+ games while simplifying payment options via seamless integrations with third-party platforms and digital wallets.

GM-Ag additionally supports all major currencies, offers multiple language options, and can be accessed by any major operating system on any device with an internet connection. The platform also features AI-based tools that help operators derive maximum revenue from each player, and data analytics that enable complete 360-degree performance visibility.

“The GMX-Ag (aggregate) platform, which provides numerous features to benefit both operators and their players, continues to gain traction, even outside our traditional markets,” said Goodman. “Additionally, on the B2B side, we provide our operators with the marketing tools they need to strengthen their customer acquisition and retention.”

Based in Las Vegas, Golden Matrix is an established gaming technology company that currently supports over 645 operators and 6.8 million players in its B2B business, and over 229,000 players in its RKings B2C segment. With a proprietary portfolio of highly modular, configurable, and scalable AI-powered gaming platforms, GMGI is strongly positioned to lead the hyper-growth iGaming industry.

For more information, visit the company’s website at www.GoldenMatrix.com. 

NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Rising Mortgage Lender REZYFi, Inc. Weathering Difficult Economy with Plans for Nationwide Expansion, Cannabis Industry Lending in Coming Months

 

• REZYFi, a Miami-based mortgage lender, servicing traditional and non-traditional loans, is expanding its operations as part of a strategy to weather recent interest rate-affected market challenges
• REZYFI’s two wholly owned subsidiaries, REZYFi Lending and ResMac Inc., work through a network of independent brokers and proprietary technology to service home owners as well as corporate clients
• REZYFi expects to grow from more than 30 states where it is licensed to holding a licensing in every state
• The company is also preparing to launch a high-margin cannabis commercial real estate lending division later this year

Emerging mortgage lender company REZYFi (stylized as “RZFI”) is building toward a planned launch for its product, which targets hard-to-finance lending markets in addition to traditional real estate consumers and includes a developing proprietary technology that will underscore its economy in turnaround time and staffing.

Housing prices rose at a record 43 percent appreciation during the height of the pandemic as the U.S. workforce reconsidered career priorities and quality of life issues, often seeking greener pastures with the hope of greater remote work opportunities (https://ibn.fm/LPcDB). But in recent weeks, the market has entered the beginnings of a correction — spurred largely by ongoing inflationary concerns and the Fed Reserve’s efforts to curb it by raising interest rates (https://ibn.fm/5j57s).

As a result of the economic pressures, a number of mortgage lenders have gone bankrupt, particularly among non-qualified (non-QM or NQM) lenders that cater to businesses and consumers that struggle to get a qualified mortgage loan (https://ibn.fm/HJFN0).

REZYFi’s 100 percent-owned subsidiaries — REZYFi Lending and ResMac Inc. — have felt the pressure as well, but are emerging as models of how companies can survive and emerge stronger.

“We’re not the most expensive, and we’re not the least expensive lender. We really pride ourselves on delivering execution and service, really not getting into the price battle, because we’re not a large company with a large balance sheet that can buy down prices and compete on price,” ResMac’s Chief People Officer Evan Tullos told HW Media this month (https://ibn.fm/FYaCw).

Tullos noted the company’s efforts to manage efficient staffing levels and expand its products and services into more commercial markets as part of its growth strategy. A significant segment of the commercial market is state-licensed operators in the cannabis industry, which have long struggled to obtain traditional loans and other banking services despite the boom they’ve enjoyed in recent years as state-by-state legalization efforts have advanced (https://ibn.fm/HNib7).

RZFI plans to launch a high-margin cannabis division later this year, during its Q4 reporting period, further signs of its expectations for its growth strategy. The company is licensed in more than 30 U.S. states and expects to expand to all remaining states.

The company has invested heavily in designing, building and implementing proprietary automated/machine learning technology to increase efficiencies and improve its outcomes, making it possible to operate its legacy business at staffing levels “meaningfully below those of its competitors,” according to the company.

For more information, visit the company’s website at www.REZYFi.com. 

NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://ibn.fm/REZY

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Odyssey Health, Inc.’s (ODYY) Brain-Related Drug Development Programs Taking Aim at Conditions with High Unmet Clinical Needs

 

• Odyssey is a medical company focused on products that offer clinical advantages to unmet clinical needs
• Its brain-related drug development programs are currently focused on treatments for concussion and the Niemann Pick Type-C (“NPC”) disease, both of which do not currently have approved treatments
• The company is also developing medical devices such as the intranasal drug delivery device, CardioMap, and Save-A-Life

Scientists and specialists describe concussion, which is also referred to as mild traumatic brain injury (“mTBI”), as a spectrum. On the one hand, some concussed patients fully recover and do not require medical intervention or attention; on the other, some patients experience consequences, with some lasting for a prolonged period (https://ibn.fm/Z45JF).

This variability underscores the fact that every brain injury develops differently, a fact that has previously somewhat impeded treatment development. In fact, there is currently no FDA-approved drug for concussion. However, organizations such as Odyssey Health (OTC: ODYY), a medical company focused on unique, life-saving medical products that offer clinical advantages to unmet clinical needs, are exploring different approaches that may birth a treatment.

Odyssey’s approach focuses on minimizing or eliminating the effects of a blow or jolt on the brain. This has led to the development of a fully synthetic, non-naturally occurring neurosteroid known as PRV-002, intended to treat mTBI. Designed to be administered within a few minutes of a concussive episode, PRV-002 induces an intracellular steroid receptor in brain cells, with the stimulation of this receptor activating multiple gene response elements that promote transcription of anti-inflammatories, antioxidants, and efflux channels that remove excess fluid and debris.

To put it simply, PRV-002 is intended to reduce swelling, oxidative stress, and inflammation in the brain, and restore proper blood flow to the brain, effects that often arise from mechanical injury to the brain. Moreover, this drug candidate is intended to avoid drug-induced fatigue or cognitive decline linked to prolonged use and the drug weakly activates the progesterone receptor, avoiding such side effects as infertility or clotting.

Odyssey is currently undertaking a Phase I study that seeks to evaluate the safety and tolerability of the drug candidate among healthy volunteers. Thus far, the results have evidenced that PRV-002 is safe and well tolerated, even among subjects who received multiple doses (https://ibn.fm/TLWCl). Next, the company is planning a Phase II trial, which is expected to be undertaken in military training camps, where cases of concussion are common.

“It’s time to find a treatment for concussion that expedites the return to work, play, school, and military duty; a treatment that can reduce the likelihood of long-term disease. Better helmets and rule changes can assist but will not prevent concussion,” Odyssey writes in a white paper (https://ibn.fm/6sv2T). “However, if the Odyssey drug candidate can reduce the pathological cascade of molecular events that occur in the acute phase of the injury, a substantial improvement in patient outcomes can be achieved in athletic and military settings as well as other commonplace occurrences for concussion.”

In addition to the PRV-002 drug candidate, Odyssey’s drug development pipeline also includes PRV-001, a first-in-class neurosteroid for the treatment of Niemann Pick Type-C (“NPC”) disease. NPC is a rare “autosomal recessive, lysosomal storage disorder characterized by accumulation of cholesterol and gangliosides in the brain and liver.” It is linked to neurological dysfunction with symptoms such as seizures, psychotic episodes, progressive dementia, motor impairment, and visual palsy, just to name a few. Unfortunately, there is no effective treatment for this lethal neurodegenerative disease (https://ibn.fm/5GXrs).

Odyssey is also developing medical devices: the breath-propelled intranasal delivery device designed to deliver PRV-002; CardioMap, a heart monitoring and screening device for early detection of coronary artery disease; and Save-A-Life, a handheld choking rescue device.

For more information, visit the company’s website at www.OdysseyHealthInc.com.

NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php